S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Corcept Therapeutics Stock Forecast, Price & News

-0.97 (-4.32%)
(As of 11/26/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
468,987 shs
Average Volume
570,967 shs
Market Capitalization
$2.48 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CORT News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Corcept Therapeutics logo

About Corcept Therapeutics

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.


Corcept Therapeutics (NASDAQ:CORT) Shares Gap Up to $20.68
November 8, 2021 |  americanbankingnews.com
Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss
November 4, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$353.87 million
Cash Flow
$0.90 per share
Book Value
$4.68 per share


Net Income
$106.01 million
Pretax Margin




Free Float
Market Cap
$2.48 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

2.42 out of 5 stars

Medical Sector

158th out of 1,392 stocks

Pharmaceutical Preparations Industry

69th out of 670 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions

Is Corcept Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Corcept Therapeutics stock.
View analyst ratings for Corcept Therapeutics
or view top-rated stocks.

How has Corcept Therapeutics' stock been impacted by COVID-19?

Corcept Therapeutics' stock was trading at $10.95 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CORT shares have increased by 96.3% and is now trading at $21.49.
View which stocks have been most impacted by COVID-19

When is Corcept Therapeutics' next earnings date?

Corcept Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Corcept Therapeutics

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its quarterly earnings results on Wednesday, November, 3rd. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.19 by $0.05. The biotechnology company had revenue of $96.13 million for the quarter, compared to analysts' expectations of $97.75 million. Corcept Therapeutics had a trailing twelve-month return on equity of 20.31% and a net margin of 30.17%. During the same quarter in the previous year, the firm posted $0.17 EPS.
View Corcept Therapeutics' earnings history

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics updated its FY 2021 earnings guidance on Wednesday, November, 17th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $365 million-$375 million, compared to the consensus revenue estimate of $371.75 million.

What price target have analysts set for CORT?

2 Wall Street analysts have issued 12-month target prices for Corcept Therapeutics' shares. Their forecasts range from $29.00 to $29.00. On average, they expect Corcept Therapeutics' share price to reach $29.00 in the next twelve months. This suggests a possible upside of 34.9% from the stock's current price.
View analysts' price targets for Corcept Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Corcept Therapeutics' key executives?

Corcept Therapeutics' management team includes the following people:
  • Joseph K. Belanoff, President, Chief Executive Officer & Director
  • Atabak Mokari, Chief Financial Officer
  • Hazel Hunt, Chief Scientific Officer
  • Sean Maduck, Chief Commercial Officer (LinkedIn Profile)
  • William Guyer, Chief Development Officer

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?

6 employees have rated Corcept Therapeutics CEO Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among Corcept Therapeutics' employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.51%), Renaissance Technologies LLC (7.14%), Ingalls & Snyder LLC (6.08%), Dimensional Fund Advisors LP (2.25%), Geode Capital Management LLC (1.56%) and Arrowstreet Capital Limited Partnership (1.29%). Company insiders that own Corcept Therapeutics stock include Daniel N Swisher Jr, G Leonard Baker Jr, G Leonard Baker, Jr, Gary Charles Robb, Joseph Douglas Lyon and Sean Maduck.
View institutional ownership trends for Corcept Therapeutics

Which institutional investors are selling Corcept Therapeutics stock?

CORT stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Dimensional Fund Advisors LP, LSV Asset Management, American Century Companies Inc., UBS Group AG, Cowen AND Company LLC, Janus Henderson Group PLC, and Citadel Advisors LLC. Company insiders that have sold Corcept Therapeutics company stock in the last year include Daniel N Swisher Jr, Gary Charles Robb, Joseph Douglas Lyon, and Sean Maduck.
View insider buying and selling activity for Corcept Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Corcept Therapeutics stock?

CORT stock was acquired by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Boston Trust Walden Corp, Epoch Investment Partners Inc., Invesco Ltd., Morgan Stanley, Trustcore Financial Services LLC, Jupiter Asset Management Ltd., and Alliancebernstein L.P.. Company insiders that have bought Corcept Therapeutics stock in the last two years include G Leonard Baker Jr, and G Leonard Baker, Jr.
View insider buying and selling activity for Corcept Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Corcept Therapeutics?

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $21.49.

How much money does Corcept Therapeutics make?

Corcept Therapeutics has a market capitalization of $2.48 billion and generates $353.87 million in revenue each year. The biotechnology company earns $106.01 million in net income (profit) each year or $0.83 on an earnings per share basis.

How many employees does Corcept Therapeutics have?

Corcept Therapeutics employs 236 workers across the globe.

When was Corcept Therapeutics founded?

Corcept Therapeutics was founded in 1998.

What is Corcept Therapeutics' official website?

The official website for Corcept Therapeutics is www.corcept.com.

Where are Corcept Therapeutics' headquarters?

Corcept Therapeutics is headquartered at 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at (650) 327-3270, via email at [email protected], or via fax at 650-327-3218.

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.